|
CF102
Drug
Product
CF102 is an oral small molecule formulated in a capsule. The active ingredient
in CF102 is Cl-IB-MECA, a highly specific and selective agonist at the
A3 adenosine receptor (A3AR).
Drug
Pharmacology
CF102 has potent anti-cancer, particularly against hepatocellular carcinoma,
and anti-inflammatory activity demonstrated in pre-clinical animal models
of liver inflammation. CF102 also inhibits the replication of Hepatitis
C viruses (HCV) .
Mechanism
of action
CF102 induces de-regulation of the NF-kB and
Wnt signal transduction pathways resulting in apoptosis of HCC cells.
The anti-viral effect was found to be mediated via the marked inhibition
of NS5A, a nonstructural protein essential for HCV replication that has
been implicated in IFN resistance in vivo.
Safety
The safety of CF102 has been demonstrated in preclinical and Phase I clinical
studies.
Efficacy
CF102 is currently being tested in Phase I/II studies in patients with
HCC and HCV. |
